What Biocytogen does

Biocytogen (百奥赛图) is a global biopharmaceutical company headquartered in Beijing, China, that operates an integrated drug discovery and preclinical research business centered on proprietary genetically engineered mouse platforms. The company was originally founded in Massachusetts, USA in 2008 with its Chinese entity established in 2009, and is dual-listed on the Shanghai STAR Market (688796.SH) and Hong Kong Stock Exchange (02315.HK), with founder Dr. Yuelei Shen serving as Chairman and CEO.

The company's core technology is its proprietary SUPCE (Size-Unlimited Precision Chromosome Engineering) gene editing platform, which enables large fragment in-situ replacement of antibody genes. SUPCE forms the foundation of the RenMice platform family, which includes RenMab for fully human monoclonal antibodies, RenLite for bispecific antibodies with common light chain technology, RenNano for fully human heavy-chain antibodies (nanobodies/VHH), and RenTCR mimic for targeting intracellular antigens through MHC-peptide complexes. These platforms support the company's "Thousand Antibodies Thousand Targets" (千鼠万抗) initiative, which has produced a library of 1M+ fully human antibody sequences against 1,000+ antigens. The company also operates the BioMice sub-brand for animal model and cell line sales, and provides preclinical pharmacology, PK/PD, and non-GLP toxicity services across oncology, autoimmune/inflammatory, metabolic, neuroscience, cardiovascular, and ophthalmology disease areas.

Biocytogen monetizes through four primary revenue streams: (1) preclinical CRO services including pharmacology and efficacy studies; (2) platform licensing of RenMice platforms to pharmaceutical partners; (3) drug co-development and asset transfer through upfront payments, milestones, and royalties; and (4) animal model sales. The company serves 200+ pharmaceutical and biotechnology customers globally, including Merck (Germany), BeiGene, Innovent Biologics, Xencor, Alexion Pharmaceuticals, and others, and has signed 350+ cumulative drug co-development/licensing agreements as of December 2025. Operations span Beijing (headquarters), Shanghai, and Haimen in China; Waltham (37,000 sq ft R&D facility), South San Francisco, and San Diego in the US; and Heidelberg (Biocytogen Europe Innovation Center) in Germany, with animal model sales reaching 20+ countries.

Name

Biocytogen

Legal name

百奥赛图（北京）医药科技股份有限公司

Website

https://bbctg.com.cn

Company type

Public

Founded year

2009

Operating status

Operating

Short description

Biocytogen (百奥赛图) is a Beijing-headquartered, dual-listed biotech (Shanghai STAR and HKEX) that develops proprietary RenMice humanized antibody discovery platforms powered by SUPCE gene editing technology, provides preclinical CRO services, and licenses/co-develops antibody assets with global pharmaceutical and biotechnology companies.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CRO Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Bispecific & Multispecific Antibodies (HLAAAAAF), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• Antibody discovery platforms
• Preclinical CRO services
• Humanized mouse models
• Gene editing services
• Bispecific antibody development

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. Preclinical CRO Services: Provides preclinical pharmacology and efficacy services, gene editing services, and animal model provision to pharmaceutical and biotech companies globally. Services include in vivo pharmacology, in vitro pharmacology, PK/PD studies, and non-GLP toxicity studies.
2. Platform Licensing: Licenses proprietary RenMice platforms (RenMab, RenLite, RenNano, RenTCR, RenTCR mimic) to pharmaceutical and biotech companies for antibody discovery. Generates licensing fees and milestone payments.
3. Drug Co-development and Asset Transfer: Co-develops and out-licenses antibody drug candidates discovered through the 'Thousand Antibodies Thousand Targets' program. Generates upfront payments, milestone payments, and royalties on product sales.
4. Animal Model Sales: Sells genetically engineered animal models including humanized mice, immunodeficient models, and disease models to research institutions and pharmaceutical companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Biocytogen develops proprietary RenMice antibody discovery platforms (RenMab, RenLite, RenNano, RenTCR mimic) built on its SUPCE gene editing technology for generating fully human monoclonal, bispecific, heavy-chain, and TCR-mimic antibodies. The company also produces and sells genetically engineered animal and cell line models, provides custom gene editing services, and conducts preclinical pharmacology, PK/PD, and efficacy/toxicity studies for global pharmaceutical and biotechnology partners. Its Thousand Mouse Thousand Antibody program has produced over 1 million fully human antibody sequences across more than 1,000 targets.

Product overview

Biocytogen is a global innovation-driven biopharmaceutical company that has developed a comprehensive drug discovery ecosystem centered on its proprietary RenMice® fully human antibody platforms. The core product portfolio includes five integrated platforms: RenMab® for monoclonal antibodies, RenLite® for bispecific antibodies, RenNano® for heavy chain antibodies (nanobodies), RenTCR mimic™ for intracellular antigens, and a GPCR antibody platform. These platforms are powered by the company's proprietary SUPCE™ gene editing technology and support the large-scale 'Thousand Mouse Thousand Antibody' initiative. Biocytogen also provides preclinical services including gene editing services, animal models and cell lines (BioMice sub-brand), pharmacology and efficacy studies, and PK/PD analysis. The company operates disease-specific solutions across oncology, autoimmune/inflammatory diseases, metabolic disorders, neuroscience, cardiovascular/cerebrovascular conditions, and ophthalmology. As of December 2025, Biocytogen has signed over 350 drug co-development/licensing agreements globally.

Differentiator

Problem solved

Functional benefit

Brands

• 百奥动物 (BioMice): Sub-brand for genetically engineered animal and cell models, offering thousands of ready-made drug target humanized animal/cell models for preclinical efficacy, safety evaluation, and mechanism research.

Quantifiable outcome

• 8,600+ drug evaluation projects completed
• +6 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Twelve partnerships are on record, tiered core and major.

• Merck (Germany)coreOEM/ Whitelabel/ Licensing Partner · 1 September 2022Licensed RenMice platform for antibody discovery and preclinical antibody drug co-development through the Thousand Antibodies Thousand Targets program.
• BeiGenecoreOEM/ Whitelabel/ Licensing PartnerLicensed RenMice platform for therapeutic antibody development.
• Innovent BiologicscoreOEM/ Whitelabel/ Licensing PartnerLicensed RenMice platform for antibody drug discovery.
• XencorcoreStrategic or Co-development PartnerStrategic partnership using RenMice platform for bispecific antibody development.
• Rongchang BiologycoreStrategic or Co-development PartnerPreclinical antibody drug co-development and licensing partnership. Joint advancement of clinical stage antibody drug molecules.
• TRACON PharmaceuticalscoreStrategic or Co-development PartnerJoint advancement of preclinical and clinical stage antibody drug molecules.
• Qidai PharmaceuticalscoreStrategic or Co-development PartnerJoint advancement of preclinical and clinical stage antibody drug molecules.
• Huarun BiologymajorStrategic or Co-development PartnerPreclinical antibody drug co-development through Thousand Antibodies Thousand Targets program.
• Nanjing TianqingmajorStrategic or Co-development PartnerPreclinical antibody drug co-development through Thousand Antibodies Thousand Targets program.
• LiberoThera (Japan)majorStrategic or Co-development PartnerPreclinical antibody drug co-development for Japanese market.
• Alexion PharmaceuticalsmajorStrategic or Co-development PartnerCollaboration in Genomic Medicine Preclinical Pharmacology for novel therapeutic development.
• Be BiopharmamajorStrategic or Co-development PartnerDevelopment of five B-NDG hIL6 models including Fabre, MPS-IV, Niemann Pick A/B, Hemophilia B, and Hypophosphatasia programs.

Scale indicators13 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• AbCellera Biologics: AbCellera operates a leading antibody discovery platform using single-cell microfluidic screening, partnering with pharma to discover fully human therapeutic antibodies — directly comparable to Biocytogen's RenMice-based platform licensing model.
• Regeneron Pharmaceuticals: Regeneron's VelocImmune humanized mouse platform is the closest analog to Biocytogen's RenMice — both generate fully human antibodies from genetically engineered mice and license them to pharma partners globally.
• GenScript Biotech: GenScript is a China-headquartered life sciences services and cell therapy company offering gene synthesis, protein/antibody services, preclinical animal models and CRO services — direct overlap with Biocytogen's gene editing, animal models and preclinical CRO business.
• Cyagen Biosciences: Cyagen is a China-based gene editing and humanized mouse model provider with comparable offerings in custom KO/KI mice and preclinical research models — direct competition to Biocytogen's gene editing services and animal model catalog.
• Taconic Biosciences: Taconic is a global supplier of genetically engineered mouse models and related preclinical research services — comparable to Biocytogen's BioMice animal model portfolio and gene-humanized model offerings.

Broad incumbents

• WuXi Biologics: WuXi Biologics is a much larger China-based biologics CRO/CDMO offering end-to-end antibody discovery, development and manufacturing — broader scope but overlapping target customers and comparable fully human antibody discovery services to Biocytogen's RenMice platforms.
• Pharmaron: Pharmaron is a China-founded global CRO/CDMO offering preclinical pharmacology, animal models and biologics services — comparable to Biocytogen's preclinical CRO services arm across oncology, autoimmune and metabolic disease models.
• Charles River Laboratories: Charles River is a leading global preclinical CRO providing animal models, in vivo pharmacology and safety assessment services — overlapping with Biocytogen's preclinical pharmacology and animal model sales business.

Emerging players

• Harbour BioMed: Harbour BioMed operates the H2L2 and HCAb transgenic mouse platforms for fully human antibody discovery and out-licenses assets to global pharma — emerging peer with overlapping platform licensing model and therapeutic antibody pipeline.
• Crown Bioscience: Crown Bioscience (JSR Life Sciences) provides preclinical oncology and immuno-oncology CRO services including humanized mouse models and in vivo pharmacology — comparable to Biocytogen's oncology preclinical solutions and humanized mouse offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocytogen